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Abstract
Background: Spontaneous abortion is one of the most common complications in early pregnancy. A preventive
test to identify women who will experience a miscarriage, even before first symptoms occur, is not established.
Activation of maternal immunological tolerance seems to be essential for early fetal development and various
cytokines have been described in different stages of pregnancy. Therefore, we aimed to investigate if chemokine
levels at the time of pregnancy testing relative to human Choriogonadotropin (hCG) are altered in patients who
will experience a miscarriage in this pregnancy.
Methods: We obtained blood samples from 39 women. Dependent on the follow-up, patients with a positive
pregnancy test were subsequently divided in two groups: ongoing pregnancy (n = 22) and miscarriage (n = 17) in
this pregnancy. Immunological and endocrine profiling of maternal plasma at the time of pregnancy testing (5th
week of gestation) was performed for each group at the time of pregnancy test using Multiplex and ELISA analysis.
Results: hCG was significantly decreased in patients with abortion whereas levels of IL-1ra, MIP-1a and TNF-alpha
were significantly increased. GCSF/ IL-1ra-ratio was 1.66-fold increased in patients with ongoing pregnancy. TGF-
beta /MIP1a-ratio was significantly 3.45-times higher in patients with miscarriage. Comparing patients with ongoing
pregnancy to patients experiencing a miscarriage, we could demonstrate significant alterations of the ratios MIP1a/
hCG, IL-1ra/hCG, TNFalpha/hCG, MCP1/hCG, IL-6/hCG, TPO/hCG and TGF-beta1/hCG. The strongest effects were seen
for the ratio MIP1a/hCG, IL-1ra/hCG and TNFalpha/hCG.
Conclusions: We have shown that cytokines in relation to hCG after 4 weeks of gestation are significantly altered in
women with miscarriage, promising potential as a prognostic biomarker.
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Background
Spontaneous abortion is one of the most common com-
plications in early pregnancy and affects 10–20% of all
pregnancies [1–5]. Symptoms include vaginal bleeding,
and/or uterine cramping, but only 28% of symptomatic
patients are experiencing spontaneous abortions later in
pregnancy [6, 7]. In clinical practice, ultrasound is per-
formed to verify the embryos viability [1]. However, as
ultrasound cannot determine pregnancy progress, differ-
ent hormone assessments have been published in order
to help predict pregnancy outcome, such as human
chorionic gonadotropin (hCG), progesterone, kisspeptin,
activin A, activin B, follistatin, CA-125, pregnancy asso-
ciated plasma protein A (PAPP-A) or macrophage in-
hibitory cytokine-1 [1, 2, 4, 6, 8–13]. However, their
clinical significance remains fair.
Miscarriage occurs in more than 80% in the first 12 weeks
of gestation and presents an enormous distress for the pa-
tient and challenges the medical professionals, especially as
pregnancy outcome is difficult to estimate when the patient
presents with the first symptoms [1, 2, 4, 13]. Moreover, pa-
tients with a previous abortion present with a higher risk of
severe complications in the following pregnancy, such as
preeclampsia or preterm birth [2, 14, 15].
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The causes of early pregnancy loss are various, includ-
ing cytogenetic abnormalities, maternal comorbidities
(eg. diabetes mellitus, lupus erythematosus), uterine mal-
formations, smoking as well as inadequate placental de-
velopment [2, 3].
Activation of maternal immunological tolerance seems
to be essential for early fetal development and implant-
ation [16] and various cytokines have been described in
different stages of pregnancy [17].
For example, lower levels of interleukin 1-receptor an-
tagonist (IL-1ra) prior to embryo transfer were associ-
ated with lower pregnancy rates [18] . Higher levels of
Thyreoperoxidase (TPO) and lower concentrations of
Granulocyte-Colony Stimulating Factor (GCSF) were
significantly associated with the risk of spontaneous
abortion in women prior to report of miscarriage. Con-
cerning TPO, this effect is not evident starting before
approximately 8 weeks of gestation. However, GCSF
alone was only predictive when focusing on women with
an upcoming miscarriage within 14 days [17]. Further-
more, chemokine ligand 3 (CCL3)/macrophage inflam-
matory protein 1-alpha (MIP-1a) is recognized as a local
chemoattractant for natural killer cells, whose increased
levels in decidual tissue are associated with recurrent
pregnancy losses in decidual tissue within the first 10
weeks of gestation [19]. In addition, transforming growth
factor (TGF) beta-1 is described as an important factor
in immunological reactions and immunological tolerance
and shows a lower expression in peripheral blood mono-
nuclear cell cultures of women who experience an abor-
tion or biochemical pregnancy, measured at the time
before oocyte retrieval. [20]. Furthermore, hCG itself, es-
sential in early pregnancy, cause an increase in regula-
tory T-cells, has effects on cytokine production, such as
an increase in IL-1beta- levels [21], and seems to possess
an important role as modulator of immune tolerance
during pregnancy [22].
A shift between Th1- and Th2- guided immunological
response also seems to play an important role in early
pregnancy. The cytokine balance towards Th2-cytokines
like Interleukin (IL)-6, as well as tumor necrosis factor
(TNF)-alpha is considered important in early pregnancy
in maternal blood [23, 24] . Various factors have their in-
fluence on this balance, eg. CCL2 or MIP-1 is considered
to cause a shift towards the Th2-response of decidual
leukocytes [25]. However, in contrary to this observa-
tion, serum levels of CCL-2/macrophage inflammatory
protein (MIP-1) were elevated in women with recurrent
spontaneous abortion (RSA) after spontaneous abortion
occurred [26], whereas other studies did not see any sig-
nificant alteration [5].
Most of the currently available studies evaluate symp-
tomatic women, therefore we are the first ones trying to
develop biomarkers that are usable even before patients
become symptomatic in order to identify women who
will experience a miscarriage.
The development of a predictive test for miscarriages
can be a helpful instrument to reassure patients on one
hand, but also to identify patients who will develop a
miscarriage on the other hand and therefore not to pro-
long unnecessary suffering of the patient. Last, but not
least, it may someday lead to potential therapies for such
patients [11].
Methods
The prospective pilot study was approved by Heidelberg
University Ethical Committee (protocol S-243/2015) and
the experimental testing complied with the principles
specified in the Declaration of Helsinki.
Blood samples were obtained at the time of pregnancy
testing (5th week of gestation) after informed consent
from women who underwent ovarian hyperstimulation
to perform in vitro fertilization by IVF or ICSI during
the period 05/15–05/16 at the University Hospital in
Heidelberg, Germany.
Exclusion criteria were autoimmune diseases, essential
hypertonia, diabetes mellitus or the intake of confound-
ing medication (e.g. acetylsalicylic acid).
Dependent on the follow-up, patients with a positive
pregnancy test were subsequently divided in two groups:
(1) patients with ongoing pregnancy (n = 22) and (2) pa-
tients with miscarriage (missed abortion, abortus incom-
pletus or abortus completus, n = 17) in the first
trimester of this pregnancy.
Immunological and endocrine profiling of maternal
plasma of women with and without miscarriage was per-
formed for each group at the time of pregnancy testing,
in order to predict pregnancy outcome.
Determination of cytokine levels
IL-6, TNFalpha, (Luminex Performance Assay, Human
High Sensitivity Cytokine Base Kit A; R&D systems,
Wiesbaden, Germany), IL-1ra, CCL2/MCP-1, CCL3/
MIP-1 alpha, G-CSF, Thrombopoietin/Tpo (Human
Luminex Performance Assay Base Kit, Panel A; R&D
systems, Wiesbaden, Germany), TGF-beta 1 (Luminex
Performance Assay 3-plex Kit; R&D systems, Wies-
baden, Germany) were determined in 39 samples using
Multiplex and ELISA analysis. Assays were performed
according to the instructions of the manufacturer. Mea-
surements were performed as pg/ml and values given as
mean+/− SEM.
Determination of hCG-levels
hCG-levels (mIU/ml, mean+/− SEM) were measured
routinely in clinical practice at the time of pregnancy
testing from central laboratory, University Hospital Hei-
delberg, Germany.
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Statistics
Statistical analysis was performed with SPSS® Version
24, IBM, Armonk, USA. p ≤ 0.05 was considered to be
significant.
Results
There was no significant difference in age (33.64 ± 6.49 years
vs. 33.94 ± 4.4 years), nor in body mass index in group 1
and 2 with 23.81 ± 4.29 kg/m2 in group 1 vs. 26.48 ±
5.27 kg/m2 in group 2 (Table 1) or transfer day (Table 2).
hCG-results and immunological profiles of patients
with ongoing pregnancy (n = 22, Nr. 1–22) and miscar-
riage (n = 17, Nr. 23–39) were analysed. Quantitative dif-
ference in GCSF-, MCP-1-, TPO- or IL-6-expression
showed a trend towards a change in values, however did
not reach statistical significance.
hCG levels, were significantly decreased in patients
with miscarriage compared to those with ongoing preg-
nancy (151.75 ± 25.29 IU/l vs. 351.27 ± 111.02 IU/l, p <
0.05) However, they were within normal limits and
therefore not predictive for pregnancy outcome.
Similarly, levels of IL-1ra (655.80 ± 78.80 pg/ml vs. 398.69 ±
32.73 pg/ml, p < 0.01), MIP-1a (73.74 ± 9.91 pg/ml vs. 34.20±
8.25 pg/ml, p < 0.01) and TNF-alpha (5.11 ± 0.40 pg/ml vs.
4.00 ± 0.26 pg/ml, p < 0.05) were significantly increased.
In order to get a potentially more stable predictor, we
investigated if the relative expressions of immunological
factors among themselves show a significant alteration.
Here, we found that the ratio of GCSF to IL-1ra was
1.66-fold decreased (p < 0.05) in patients suffering from
miscarriage (0.043 ± 0.005) compared to patients with
ongoing pregnancy (0.072 ± 0.009; p < 0.05). In addition,
the ratio of MIP1a to TGF-beta was 3,45-times higher in
patients with miscarriages (0.012 ± 0.005) compared to
patients without ongoing pregnancy (0.004 ± 0.001; p <
0.05) (data are shown in Table 3). The other relative ex-
pressions of the different cytokines analysed did not
show significant changes.
Due to the observation, that patients with miscarriage
showed lower levels of hCG and increased levels in im-
munological factors at the same time, we investigated if
we get a higher predictive value, if we analyse the rela-
tive expression of immunological factors compared to
hCG (Table 4).
Comparing patients with ongoing pregnancy to pa-
tients experiencing a miscarriage, we could demonstrate
significant alterations of the ratios MIP1a/hCG (0.16 ±
0.04 pg/mIU vs. 1.02 ± 0.38 pg/mIU, p < 0.05), IL-1ra/
hCG (2.22 ± 0.72 pg/mIU vs. 7.83 ± 2.30 pg/mIU, p <
0.05), TNFalpha /hCG (0.02 ± 0.01 pg/mIU vs. 0.07 ±
0.02 pg/mIU, p < 0.05), MCP1/hCG (0.50 ± 0.16 pg/mIU
vs. 1.44 ± 0.40 pg/mIU, p < 0.05), IL-6/hCG (0.007 ±
0.002 pg/mIU vs 0.016 ± 0.003 pg/mIU, p < 0.05), TPO/
hCG (2.50 ± 0.70 pg/mIU vs. 5.47 ± 1.31 pg/mIU, p <
0.05) and TGF-beta1/hCG (68.04 ± 22.37 pg/mIU vs.
149.35 ± 33.89 pg/mIU, p < 0.05).
Altogether, we observe a significant alteration towards the
immunological factor in relation to hCG levels in patients,
who experience a miscarriage in their course of pregnancy.
The strongest effects were seen for the ratio MIP1a/
hCG (ratio 0.15) for patients with ongoing pregnancy
compared to patients with abortion, IL-1ra (ratio 0.28)
and TNFalpha (ratio 0.29).
Discussion
Spontaneous abortion is one of the most common com-
plications in early pregnancy and affects 10–20% of all
pregnancies [1–5].
There is currently no successful therapeutical ap-
proach established, although various approaches have
been tested [5, 27].
The development of an early-screening test to identify
patients who are at risk to suffer from abortion in the
actual pregnancy can be useful in manyfold ways: a mis-
carriage presents an enormous distress for the patient
and a predictive test with a negative result could be used
to reassure anxious patients [1, 2, 4, 5, 13]. On the other
hand, a predictive test with a positive result can warn
the patients in a very early stage of pregnancy [5], and
will prohibit unnecessary prolongation of the current
pregnancy by supplementation of high doses of proges-
terone, as progesterone prevents bleeding.
Most of the studies trying to establish biomarkers
to follow this approach include symptomatic women
at a later stage of pregnancy. One of the most inter-
esting aspects concerning our data is the fact that we
discovered in total 3 absolute and 9 relative alter-
ations in immunological profile parameters of asymp-
tomatic patients at the time of first pregnancy testing,
that could present a very helpful tool in clinical prac-
tice to discover patients at risk even before first
symptoms occur.
Another interesting point in screening for altered
potential biomarkers is the fact that the discovered
proteins in maternal plasma may help to identify po-
tential therapeutical targets in the long run [5, 11].
Cytokines play an important role in implantation
and early pregnancy [16, 28]. For example, IL-1
Table 1 Patient characteristics. There was no significant
difference in age or BMI between the two groups. All values are
given in mean ± STD
Ongoing pregnancy Abortion p-value
Age (years) 33.64 ± 6.49 33.94 ± 4.4 0.87
BMI (kg/m2) 23.81 ± 4.29 26.48 ± 5.27 0.12
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Table 2 Embryo quality and day of embryo transfer
Nr Abortion Ongoing pregnacy Embryo quality Embryo transfer
1 no yes 6C, 8B day 3
2 no yes 4AA, 4AA day 5
3 no yes 4AB, 3AA day 5
4 no yes 2A, 4B day 2
5 no yes Morula, blastocyst 1 day 5
6 no yes 4BA, blastocyst 1 day 5
7 no yes 4AA hatch day 5
8 no yes 5B day 2
9 no yes Blastocyst 1 day 5
10 no yes 9B day 3
11 no yes 4AB, 3AB day 5
12 no yes 4AA, 4AA day 5
13 no yes 12B day 4
14 no yes 3BA day 5
15 no yes Morula day 4
16 no yes 4AB, 3AB day 5
17 no yes Blastocyst 1 day 5
18 no yes Blastocyst 1 day 4
19 no yes Morula, Morula day 4
20 no yes 4A day 2
21 no yes 6C, 4B day 3
22 no yes 4BB, 4BB day 5
23 yes no Blastocyst 1, blastocyst 2 day 4
24 yes no 3AB, blastocyst 1 day 5
25 yes no 3BB day 5
26 yes no 4AA, 4AA day 5
27 yes no 4B day 2
28 yes no 11A day 4
29 yes no Blastocyst 1, blastocyst 2 day 5
30 yes no 4A, 4A day 2
31 yes no 4AA, 3AA day 5
32 yes no 2A day 2
33 yes no 4AA, Blastocyst 1 day 5
34 yes no 8A, 8C day 5
35 yes no 8B, 7C day 2
36 yes no Blastocyst 1, blastocyst 2 day 5
37 yes no 4BA, 3AA day 4
38 yes no 4AA, 4AA day 3
39 yes no 9C, 5B, 8C day 2
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receptors have been shown to be located on the early
human embryo, emphasizing the important role of
IL1-ra in early pregnancy [18]. Therefore, we aimed
to establish chemokines as biomarkers at the time of
pregnancy testing, some of which were found to be
changed in patients with proven abortions.
Especially MIP1a, IL-1ra and TNF alpha showed
promising results: not only absolute values were altered,
additionally we could demonstrate altered relative ex-
pression changes, when put in relation to hCG, poten-
tially making them even more predictive for pregnancy
outcome in such an early phase.
MCP1 (aka CCL-2) is discussed controversially in the
literature: it is considered to cause a shift towards
Th2-response, which seems to present an important
process in early pregnancy [23–25]. However, contrary
to this observation, serum levels of MCP1 in early preg-
nancy were higher in women with RSA [26], whereas
other studies did not see any significant alteration [5].
With our data we can rather support the observation
that MCP1 does not show any change concerning the
absolute values in patients with abortion during preg-
nancy. However, the ratio of MCP1/hCG varies between
women with ongoing pregnancy and women suffering
from abortion at the time of pregnancy testing already.
This emphasizes the usefulness of the chemokine/hCG
ratios compared to absolute levels.
TNF-alpha also favours a shift towards Th2-guided
immune response. Despite this fact, our data does not
answer the question which immunological pathway is
dominant in early pregnancy or abortion.
Other factors, such as TPO or IL-6 that showed al-
terations at other time points in pregnancy [17, 20],
were not significantly altered regarding the absolute
expression at this very early time point in pregnancy,
but showed altered expression when put in relation
to hCG.
This observation may be contributed to the fact
that absolute alterations may be already present at
time of pregnancy testing but do not show an effect
that allows to reach statistical significance with a
small sample size.
To screen for promising biomarkers at this very
early stage in pregnancy, we tent to enhance the
prognostic marker for later abortion by examining a
cytokines/ hCG correlation, leading to changes in
clinical management. These ratios showed very prom-
ising results and were, to our knowledge, not de-
scribed elsewhere in the literature. Due to the fact
that two potentially altered proteins are included in
this ratio, we think that these ratios are more predict-
ive for pregnancy outcome than absolute cytokine or
hCG expression levels and present therefore a high
potential for the use as a biomarker. Furthermore,
even though hCG levels were found to be significantly
decreased in patients with abortion compared to
those with ongoing pregnancy at the time of preg-
nancy testing, their levels are within normal limits
and can therefore not be used as predictive factor of
pregnancy outcome.
The limitations of this study are its small sample size
and the fact, that we only detected protein in maternal
plasma with no further validation technique. Therefore,
our results require further validation after power calcu-
lation in order evaluate the different ratios. Furthermore,
it is worth to investigate if an index involving different
chemokines can be created.
Our study included patients after ART solely. We
can’t exclude that these findings can be transmitted to
patients who conceived spontaneously. However, as
ART seems to influence cytokine profile, our findings
can be specific for patients following in-vitro-fertilization [29].
Table 3 Significant alterations of relative immunological profile.
GCSF, IL-1ra, MIP1a and TGF-beta were assessed in pg/ml
Ratio GCSF/IL-1ra MIP1a /TGF-beta 1
mean ± SEM (ongoing pregnancy) 0.072 ± 0.009 0.004 ± 0.001
mean ± SEM (abortion) 0.043 ± 0.005 0.012 ± 0.005
Ratio 1.657 0.293
p-value < 0.05 < 0.05
Table 4 Alterations in immunological profile relative to hCG-levels. MIP1a, IL-1ra, TNF alpha, MCP1, IL-6, TPO and TGF-beta1 were
assessed in pg/ml, hCG in mIU/ml
Ratio MIP1a (pg/ml)/
hCG (mIE/ml)
IL-1ra (pg/ml)/
hCG (mIE/ml)
TNF alpha(pg/ml)/
hCG (mIE/ml)
MCP1(pg/ml)/
hCG (mIE/ml)
IL-6 (pg/ml)/
hCG (mIE/ml)
TPO (pg/ml)/
hCG(mIE/ml)
TGF-beta1
(pg/ml)/
hCG(mIE/ml)
mean ± SEM
(ongoing pregnancy)
0.16 ± 0.04 2.22 ± 0.72 0.02 ± 0.01 0.5 ± 0.16 0.007 ± 0.002 2.50 ± 0.70 68.04 ± 22.37
mean ± SEM
(abortion)
1.02 ± 0.38 7.83 ± 2.30 0.07 ± 0.02 1.44 ± 0.40 0.016 ± 0.003 5.47 ± 1.31 149.35 ± 33.89
Ratio 0.15 0.28 0.29 0.35 0.44 0.45 0.45
p-value < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
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Conclusion
In conclusion, we have shown that cytokines in relation
to hCG, as well as the ratio of GCSF/IL-1ra and MIP1a/
TGF-beta1 after 4 weeks of gestation are significantly al-
tered in women with abortion, indicating their potential
use as a prognostic biomarker. Particularly the ratios of
MIP1a, IL-1ra and TNF alpha to hCG show very prom-
ising results.
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